TrialDrugs in R&D2012

Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.

Florence Namour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.